Hong Kong Med J 2023;29(Suppl 1):S12-3
Targeting androgen receptor in BQ323636.1 overexpressing oestrogen receptor-positive breast cancer to overcome aromatase inhibitor resistance: abridged secondary publication
H Tsoi1, EPS Man1, J Lok1, CN Cheng1, LS Wong2, SY Chan2, MH Leung1, WL Chan3, US Khoo1
1 Department of Pathology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China
3 Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
 
 
  1. BQ323636.1 overexpression enhances the activity of androgen receptor (AR) signalling and reverses the tumour suppressive effect of aromatase inhibitors (AI).
  2. High nuclear BQ323636.1 (BQ) and AR expression is associated with AI resistance and poorer survival in post-menopausal oestrogen receptor-positive (ER+) breast cancer patients.
  3. Co-treatment with AR inhibitor, bicalutamide can recover the therapeutic effect of AI in ER+/BQ+/AR+ breast cancer.